|Dr. Yuichi Iwaki M.D., Ph.D.||Co-Founder, Chief Exec. Officer, Pres and Exec. Director||800.46k||N/A||67|
|Mr. Ryan J. Selhorn||Chief Financial Officer and Principal Accounting Officer||58.75k||N/A||35|
|Mr. Masatsune Okajima||Head of Japanese Office and VP||429k||N/A||49|
|Dr. Kazuko Matsuda M.D., Ph.D., MPH||Chief Medical Officer||477.56k||N/A||51|
|Mr. Geoffrey G. O'Brien J.D., M.B.A.||VP||365.63k||10.56k||48|
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The companys product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
MediciNova, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 7.